NasdaqGS - Delayed Quote USD

XBiotech Inc. (XBIT)

8.21 +0.14 (+1.73%)
At close: April 25 at 4:00 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for XBIT

Recent News: XBIT

View More
XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 44% stake, while 44% is held by insiders

XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 44% stake, while 44% is held by insiders
Simply Wall St. last month
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
GlobeNewswire 3 months ago
Companies Like XBiotech (NASDAQ:XBIT) Are In A Position To Invest In Growth

Companies Like XBiotech (NASDAQ:XBIT) Are In A Position To Invest In Growth
Simply Wall St. 4 months ago
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis

Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis
GlobeNewswire 5 months ago
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
GlobeNewswire 6 months ago
Individual investors account for 50% of XBiotech Inc.'s (NASDAQ:XBIT) ownership, while insiders account for 35%

Individual investors account for 50% of XBiotech Inc.'s (NASDAQ:XBIT) ownership, while insiders account for 35%
Simply Wall St. 7 months ago
XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer

XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer
GlobeNewswire 7 months ago
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial

XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial
GlobeNewswire 8 months ago
The past three years for XBiotech (NASDAQ:XBIT) investors has not been profitable

The past three years for XBiotech (NASDAQ:XBIT) investors has not been profitable
Simply Wall St. 8 months ago
Here's Why We're Not Too Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Situation

Here's Why We're Not Too Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Situation
Simply Wall St. 9 months ago
FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients

FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients
GlobeNewswire 10 months ago

XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares
GlobeNewswire 11 months ago
View More

Related Tickers

XLS.SW Xlife Sciences AG
34.30
0.00%
 
BION.SW BB Biotech AG
40.40
-0.37%
 
EWTX Edgewise Therapeutics, Inc.
15.94
-1.06%
 
HOWL Werewolf Therapeutics, Inc.
6.21
-2.82%
 
STTK Shattuck Labs, Inc.
9.78
-1.21%
 
ASMB Assembly Biosciences, Inc.
13.36
-0.67%
 
MGTX MeiraGTx Holdings plc
4.7100
-3.09%
 
CYCN Cyclerion Therapeutics, Inc.
3.0400
+7.42%
 
NWRN.SW Newron Pharmaceuticals S.p.A.
7.08
+5.83%
 
HLVX HilleVax, Inc.
12.02
-4.45%